# A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)

> **NCT04679103** · PHASE3 · COMPLETED · sponsor: **AO GENERIUM** · enrollment: 50 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **BIOLOGICAL:** Eculizumab (JSC GENERIUM, Russia)

## Key facts

- **NCT ID:** NCT04679103
- **Lead sponsor:** AO GENERIUM
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-03
- **Primary completion:** 2020-04-20
- **Final completion:** 2020-04-20
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679103, "A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04679103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*